APUS Stock Summary and Trading Ideas (Apimeds Pharmaceuticals US | AMEX:APUS)

Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.

Apimeds Pharmaceuticals US trades on the AMEX stock market under the symbol APUS.

As of September 18, 2026, APUS stock price climbed to $1.77 with 374,768 million shares trading.

APUS has a beta of -0.40, meaning it tends to be less sensitive to market movements. APUS has a correlation of 0.00 to the broad based SPY ETF.

APUS has a market cap of $2.67 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that APUS belongs to (by Net Assets): VXF.

APUS has underperformed the market in the last year with a price return of -3.3% while the SPY ETF gained +16.8%. However, in the short term, APUS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +62.4% vs +2.3% return in SPY. But in the last 2 weeks, APUS shares have been beat by the market, returning -26.9% compared to an SPY return of -0.9%.

APUS support price is $1.47 and resistance is $1.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APUS shares will trade within this expected range on the day.